Has Memo® (Pharco Pharmaceuticals) been followed by larger or longer randomized trials since the 4‑week pilot?
Executive summary
The public record provided does not link a product called “Memo®” to Pharco Pharmaceuticals, and none of the supplied sources describe a four‑week pilot of a Pharco product by that name [1] [2]. What can be documented is that Pharco’s ravidasvir (also referred to as PPI‑668 in some reports) moved beyond early studies into much larger, longer randomized trials — including multicenter Phase 3 work in Egypt and large trials in Malaysia and Thailand — demonstrating high cure rates for hepatitis C genotype 4 and enrolling on the order of hundreds to roughly a thousand patients in follow‑on studies [3] [2] [4] [5].
1. The naming gap: “Memo®” is not present in the cited reporting
None of the supplied Pharco materials or linked analyses use the trade name “Memo®,” and the corporate pages and historical summaries instead discuss ravidasvir (PPI‑668) combined with sofosbuvir as Pharco’s investigational regimen; therefore any direct claim that “Memo® (Pharco Pharmaceuticals)” existed as a four‑week pilot in these sources cannot be substantiated from the provided documents [1] [2] [3].
2. What Pharco did pursue after early studies: large, multicenter Phase 3 and country trials
Pharco’s ravidasvir program progressed to large randomized and registrational studies: company history notes presentation of “High Virologic Response Rate” results from a large multicenter Phase 3 registrational trial of ravidasvir plus sofosbuvir in Egyptian genotype‑4 patients [2], and independent analyses of the collaborative development model describe co‑sponsored trials in Malaysia and Thailand as part of an effort to evaluate ravidasvir broadly across genotypes and patient groups [3] [5].
3. Scale and duration: trials far larger than a small pilot and designed as phase 2/3 programs
The follow‑on programs were not brief pilots; reports indicate “large‑scale clinical trials” in Malaysia and Egypt with reported cure rates in the high‑90s percent and a multi‑country phase 2/3 effort aimed at testing roughly 1,000 patients across genotypes, including those with advanced liver disease or HIV coinfection — clearly larger and longer undertakings than a single 4‑week pilot [4] [5] [3].
4. Who ran and financed the bigger trials, and what that implies about rigor and scope
The development and larger trials were run in collaboration with partners such as the Drugs for Neglected Diseases initiative (DNDi), national ministries of health in Malaysia and Thailand, and NGOs including Médecins Sans Frontières, with Pharco supplying product and manufacturing; these partnerships financed larger randomized studies intended to assess safety and efficacy across relevant populations rather than remain limited pilot experiments [3] [5].
5. Limits of the record supplied: what cannot be concluded from these sources
Because the supplied sources do not mention a four‑week pilot explicitly nor the brand name “Memo®,” it is not possible from this reporting to confirm that a named 4‑week pilot existed under that name, nor to trace a precise one‑to‑one progression from a four‑week pilot called Memo® to the larger trials; the available documents instead chronicle ravidasvir’s movement into Phase 2/3 and large multicenter trials [1] [3] [2] [4] [5].
6. Alternative interpretation and potential implicit agendas
If the question conflates two different companies or products (for example Memo Therapeutics’ potravitug, which appears in other materials but is unrelated to Pharco), confusion is understandable: separate sources show Memo Therapeutics running randomized phase 1/2 work on a transplant antibody, a wholly different program [6] [7]. Some industry and advocacy reports emphasize the access and pricing commitments tied to Pharco/DNDi trials — an implicit agenda to frame ravidasvir as an affordable global solution — which may shape how trials and outcomes are presented in promotional or access‑oriented materials [3] [5].
Conclusion
The materials provided document that Pharco’s ravidasvir program advanced from early studies to substantially larger, randomized phase 2/3 and phase 3 multicenter trials in Egypt, Malaysia and Thailand that were longer and larger than a simple four‑week pilot and that reported high cure rates; however, the record here does not identify a Pharco product called “Memo®” nor a named four‑week pilot under that label, so a direct confirmation that “Memo® (Pharco Pharmaceuticals) was followed by larger or longer randomized trials since the 4‑week pilot” cannot be fully supported without additional sources tying the name Memo® to Pharco’s ravidasvir program [3] [2] [4] [5].